Oncolytic Reovirus in Canine Mast Cell Tumor

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Hwang, Chung Chew ^a   Umeki, Saori ^a   Kubo, Masahito ^a   Hayashi, Toshiharu ^a   Shimoda, Hiroshi ^a   Mochizuki, Masami ^b   Maeda, Ken ^a   Baba, Kenji ^a   Hiraoka, Hiroko ^a   Coffey, Matt ^c   Okuda, Masaru ^a   Mizuno, Takuya ^a  

^a YAMAGUCHI UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c ONCOLYTICS BIOTECH INC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC VIRUS; RAS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG DISEASE; DRUG CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVATION; EX VIVO STUDY; FEASIBILITY STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; MAST CELL; MASTOCYTOMA; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; RAT; REOVIRUS; SINGLE DRUG DOSE; TUMOR CELL LINE; TUMOR REGRESSION; TUMOR XENOGRAFT; VETERINARY MEDICINE; VIRUS INFECTIVITY; VIRUS REPLICATION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; DOG DISEASES; DOGS; HUMANS; MAST CELLS; MASTOCYTOSIS; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; ONCOLYTIC VIROTHERAPY; REOVIRIDAE; TUMOR CELLS, CULTURED; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884488583     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073555     Document Type: Article

References (51)

1. Jemal A, Bray F, (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA: A cancer journal for clinicians 61: 69-90.
2. Butler LM, Bonnett BN, Page RL (2013) Epidemiology and the evidence-based medicine approach. In: Withrow SJ, Vail DM, Page RL, editors. Small animal clinical oncology. Missouri: Elsevier Saunders. 68-82.
3. Meerani S, Yao Y, (2010) Oncolytic viruses in cancer therapy. Eur J Sci Res 40: 156-171.
4. Patil SS, Gentschev I, Nolte I, Ogilvie G, Szalay AA, (2012) Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients. J Transl Med 10: 3.
5. Selb B, Weber B, (1994) A study of human reovirus IgG and IgA antibodies by ELISA and western blot. J Virol Methods 47: 15-25.
6. Alain T, Hirasawa K, Pon KJ, Nishikawa SG, Urbanski SJ, et al. (2002) Reovirus therapy of lymphoid malignancies. Blood 100: 4146-4153.
7. Thirukkumaran CM, Nodwell MJ, Hirasawa K, Shi ZQ, Diaz R, et al. (2010) Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic. Cancer Res 70: 2435-2444.
8. Lolkema MP, Arkenau HT, Harrington K, Roxburgh P, Morrison R, et al. (2011) A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res 17: 581-588.
9. Duncan MR, Stanish SM, Cox DC, (1978) Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol 28: 444-449.
10. Strong JE, Lee PW, (1996) The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. J Virol 70: 612-616.
11. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW, (1998) The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 17: 3351-3362.
12. Coffey MC, Strong JE, Forsyth PA, Lee PW, (1998) Reovirus therapy of tumors with activated Ras pathway. Science 282: 1332-1334.
13. Twigger K, Roulstone V, Kyula J, Karapanagiotou EM, Syrigos KN, et al. (2012) Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway. BMC Cancer 12: 368.
14. Metcalfe DD, (2005) Regulation of normal and neoplastic human mast cell development in mastocytosis. Trans Am Clin Climatol Assoc 116: 185-205.
15. London CA, Thamm DH (2013) Mast cell tumors. In: Withrow SJ, Vail DM, Page RL, editors. Small animal clinical oncology. Missouri: Elsevier Saunders. 335-355.
16. Watzinger F, Mayr B, Gamerith R, Vetter C, Lion T, (2001) Comparative analysis of ras proto-oncogene mutations in selected mammalian tumors. Mol Carcinog 30: 190-198.
17. Murua Escobar H, Günther K, Richter A, Soller JT, Winkler S, et al. (2004) Absence of ras-gene hot-spot mutations in canine fibrosarcomas and melanomas. Anticancer Res 24: 3027-3028.
18. Gordon IK, Khanna C, (2010) Modeling opportunities in comparative oncology for drug development. ILAR Journal 51: 214-220.
19. Takahashi T, Kitani S, Nagase M, Mochizuki M, Nishimura R, et al. (2001) IgG-mediated histamine release from canine mastocytoma-derived cells. Int Arch Allergy Immunol 125: 228-235.
20. Ishiguro T, Kadosawa T, Mori K, Takagi S, Okumura M, et al. (2001) Establishment and characterization of a new canine mast cell tumor cell line. J Vet Med Sci 63: 1031-1034.
21. Ohmori K, Kawarai S, Yasuda N, Tanaka A, Matsuda H, et al. (2008) Identification of c-kit mutations-independent neoplastic cell proliferation of canine mast cells. Vet Immunol Immunopathol 126: 43-53.
22. Reed LJ, Muench H, (1938) A simple method of estimating fifty per cent endpoints. Am J Epidemiol 27: 493-497.
23. Taylor SJ, Resnick RJ, Shalloway D, (2001) Nonradioactive determination of Ras-GTP levels using activated ras interaction assay. Meth Enzymol 333: 333-342.
24. Umeki S, Suzuki R, Shimojima M, Ema Y, Yanase T, et al. (2011) Characterization of monoclonal antibodies against canine P-selectin glycoprotein ligand-1 (PSGL-1). Vet Immunol Immunopathol 142: 119-125.
25. Lin T-Y, Rush LJ, London CA, (2006) Generation and characterization of bone marrow-derived cultured canine mast cells. Vet Immunol Immunopathol 113: 37-52.
26. Kawarai S, Masuda K, Ohmori K, Matsuura S, Yasuda N, et al. (2009) Cultivation and characterization of canine skin-derived mast cells. J Vet Med Sci 72: 131-140.
27. Kalesnikoff J, Galli SJ, (2011) Antiinflammatory and immunosuppressive functions of mast cells. Methods Mol Biol 677: 207-220.
28. Marcato P, Shmulevitz M, Pan D, Stoltz D, Lee PW, (2007) Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release. Mol Ther 15: 1522-1530.
29. Loken SD, Norman K, Hirasawa K, Nodwell M, Lester WM, et al. (2004) Morbidity in immunosuppressed (SCID/NOD) mice treated with reovirus (Dearing 3) as an anti-cancer biotherapeutic. Cancer Biol Ther 3: 734-738.
30. Thirukkumaran CM, Luider JM, Stewart DA, Cheng T, Lupichuk SM, et al. (2003) Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation. Blood 102: 377-387.
31. van Houdt WJ, Smakman N, van den Wollenberg DJ, Emmink BL, Veenendaal LM, et al. (2008) Transient infection of freshly isolated human colorectal tumor cells by reovirus T3D intermediate subviral particles. Cancer Gene Ther 15: 284-292.
32. Sei S, Mussio JK, Yang Q-E, Nagashima K, Parchment RE, et al. (2009) Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Mol Cancer 8: 47.
33. Errington F, White CL, Twigger KR, Rose A, Scott K, et al. (2008) Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Ther 15: 1257-1270.
34. Norman KL, Hirasawa K, Yang A-D, Shields MA, Lee PW, (2004) Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci U S A 101: 11099-11104.
35. Kim M, Williamson CT, Prudhomme J, Bebb DG, Riabowol K, et al. (2010) The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status. Oncogene 29: 3990-3996.
36. Pan D, Marcato P, Ahn D-G, Gujar S, Pan L-Z, et al. (2013) Activation of p53 by chemotherapeutic agents enhances reovirus oncolysis. PLoS ONE 8: e54006.
37. Barton ES, Forrest JC, Connolly JL, Chappell JD, Liu Y, et al. (2001) Junction adhesion molecule is a receptor for reovirus. Cell 104: 441-451.
38. Chappell JD, Gunn VL, Wetzel JD, Baer GS, Dermody TS, (1997) Mutations in type 3 reovirus that determine binding to sialic acid are contained in the fibrous tail domain of viral attachment protein sigma1. J Virol 71: 1834-1841.
39. Cho I-R, Koh SS, Min H-J, Park E-H, Srisuttee R, et al. (2010) Reovirus infection induces apoptosis of TRAIL-resistant gastric cancer cells by down-regulation of Akt activation. Int J Oncol 36: 1023-1030.
40. Clarke P, Meintzer SM, Wang Y, Moffitt LA, Richardson-Burns SM, et al. (2004) JNK regulates the release of proapoptotic mitochondrial factors in reovirus-infected cells. J Virol 78: 13132-13138.
41. Connolly JL, Rodgers SE, Clarke P, Ballard DW, Kerr LD, et al. (2000) Reovirus-induced apoptosis requires activation of transcription factor NF-κB. J Virol 74: 2981-2989.
42. Roskoski R, (2005) Structure and regulation of Kit protein-tyrosine kinase-the stem cell factor receptor. Biochem Biophys Res Commun 338: 1307-1315.
43. Heinrich MC, Blanke CD, Druker BJ, Corless CL, (2002) Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20: 1692-1703.
44. Takeuchi Y, Fujino Y, Fukushima K, Watanabe M, Nakagawa T, et al. (2012) Biological effect of tyrosine kinase inhibitors on three canine mast cell tumor cell lines with various KIT statuses. J Vet Pharmacol Ther 35: 97-104.
45. Adair RA, Scott KJ, Fraser S, Errington-Mais F, Pandha H, et al. (2012) Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells. Int J Cancer 132: 2327-2338.
46. Ilett EJ, Barcena M, Errington-Mais F, Griffin S, Harrington KJ, et al. (2011) Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization. Clin Cancer Res 17: 2767-2776.
47. Errington F, Steele L, Prestwich R, Harrington KJ, Pandha HS, et al. (2008) Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol 180: 6018-6026.
48. Fukumi H, Takeuchi Y, Ishida M, Saito H, (1969) Serological epidemiology of reovirus infection. Jpn J Med Sci Biol 22: 13-21.
49. Murakami T, Kato H, (1975) Reovirus antibody patterns in dogs: a trial for the application of principal component analysis to seroepidemiology. Natl Inst Anim Health Q (Tokyo) 15: 8-14.
50. Decaro N, Campolo M, Desario C, Ricci D, Camero M, et al. (2005) Virological and molecular characterization of a mammalian orthoreovirus type 3 strain isolated from a dog in Italy. Vet Microbiol 109: 19-27.
51. Prestwich RJ, Errington F, Diaz RM, Pandha HS, Harrington KJ, et al. (2009) The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther 20: 1119-1132.